Cargando…

Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization

To report a patient with juxtapapillary choroidal osteoma (CO) with serous retinal detachment (SRD) not associated with choroidal neovascularization (CNV) who was successfully treated with a single intravitreal injection of bevacizumab. A 20-year-old woman presented with decreased vision in her righ...

Descripción completa

Detalles Bibliográficos
Autores principales: Najafabadi, Farhad Fazel, Hendimarjan, Seyyed Moien, Zarrin, Yasaman, Najafabadi, Mohammadreza Fazel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795400/
https://www.ncbi.nlm.nih.gov/pubmed/27051495
http://dx.doi.org/10.4103/2008-322X.176905
_version_ 1782421604207165440
author Najafabadi, Farhad Fazel
Hendimarjan, Seyyed Moien
Zarrin, Yasaman
Najafabadi, Mohammadreza Fazel
author_facet Najafabadi, Farhad Fazel
Hendimarjan, Seyyed Moien
Zarrin, Yasaman
Najafabadi, Mohammadreza Fazel
author_sort Najafabadi, Farhad Fazel
collection PubMed
description To report a patient with juxtapapillary choroidal osteoma (CO) with serous retinal detachment (SRD) not associated with choroidal neovascularization (CNV) who was successfully treated with a single intravitreal injection of bevacizumab. A 20-year-old woman presented with decreased vision in her right eye. Ultrasonography, fundus autofluorescence, fluorescein angiography (FA) and optical coherence tomography (OCT) were performed. She was diagnosed with juxtapapillary CO with SRD in the absence of CNV. The treatment involved a single intravitreal injection of bevacizumab. Visual acuity (VA) was 20/100 pre-injection which was dramatically improved to 20/20 one week after the injection without any additional treatment. Fundus examination and OCT one week after the injection revealed complete absorption of the subretinal fluid (SRF) in the macula. Eighteen months after the injection, vision remained stable and she did not show re-accumulation of SRF in her right eye. Intravitreal injection of bevacizumab may be effective in managing CO associated with SRF without CNV.
format Online
Article
Text
id pubmed-4795400
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47954002016-04-05 Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization Najafabadi, Farhad Fazel Hendimarjan, Seyyed Moien Zarrin, Yasaman Najafabadi, Mohammadreza Fazel J Ophthalmic Vis Res Case Report To report a patient with juxtapapillary choroidal osteoma (CO) with serous retinal detachment (SRD) not associated with choroidal neovascularization (CNV) who was successfully treated with a single intravitreal injection of bevacizumab. A 20-year-old woman presented with decreased vision in her right eye. Ultrasonography, fundus autofluorescence, fluorescein angiography (FA) and optical coherence tomography (OCT) were performed. She was diagnosed with juxtapapillary CO with SRD in the absence of CNV. The treatment involved a single intravitreal injection of bevacizumab. Visual acuity (VA) was 20/100 pre-injection which was dramatically improved to 20/20 one week after the injection without any additional treatment. Fundus examination and OCT one week after the injection revealed complete absorption of the subretinal fluid (SRF) in the macula. Eighteen months after the injection, vision remained stable and she did not show re-accumulation of SRF in her right eye. Intravitreal injection of bevacizumab may be effective in managing CO associated with SRF without CNV. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4795400/ /pubmed/27051495 http://dx.doi.org/10.4103/2008-322X.176905 Text en Copyright: © Journal of Ophthalmic and Vision Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Case Report
Najafabadi, Farhad Fazel
Hendimarjan, Seyyed Moien
Zarrin, Yasaman
Najafabadi, Mohammadreza Fazel
Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization
title Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization
title_full Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization
title_fullStr Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization
title_full_unstemmed Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization
title_short Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization
title_sort intravitreal bevacizumab for management of choroidal osteoma without choroidal neovascularization
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795400/
https://www.ncbi.nlm.nih.gov/pubmed/27051495
http://dx.doi.org/10.4103/2008-322X.176905
work_keys_str_mv AT najafabadifarhadfazel intravitrealbevacizumabformanagementofchoroidalosteomawithoutchoroidalneovascularization
AT hendimarjanseyyedmoien intravitrealbevacizumabformanagementofchoroidalosteomawithoutchoroidalneovascularization
AT zarrinyasaman intravitrealbevacizumabformanagementofchoroidalosteomawithoutchoroidalneovascularization
AT najafabadimohammadrezafazel intravitrealbevacizumabformanagementofchoroidalosteomawithoutchoroidalneovascularization